

Patent Docket P1071P1D3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Ross G. Clark et al. Serial No.: 09/724,157 Filed: 28 November 2000 For: INSULIN-LIKE GROWTH FACTOR AGONIST MOLECULES	Group Art Unit: 1647 Examiner: David Romeo CERTIFICATE OF FACSIMILE TRANSMISSION March 27, 2002 : Date of transmission I hereby certify that this correspondence, consisting of amendment After Final Rejection and Amendment Transmittal, is being facsimile transmitted to the Assistant Commissioner of Patents, Washington, D.C. 20231. Janet E. Hasak
---	---

5/B
M.G.J
12/12/02

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed March 7, 2002, please amend the above-identified application as follows.

IN THE CLAIMS:

Please amend claim 1 as follows:

B1 Subcl
1. (amended) A peptide comprising an amino acid sequence that is
SEQ ID NO:108.

REMARKS

Claim 1 has been amended to recite SEQ ID NO:108 and not SEQ ID NO:109. Applicants specifically reserve the right to pursue an application directed to the embodiment involving SEQ ID NO:109.

The Examiner has required restriction to one of the following inventions under 35 USC §121:

I. Claims 1-7, to the extent that they are drawn to a peptide comprising the amino acid sequence of SEQ ID NO:108; and

II. Claims 1-7, to the extent that they are drawn to a peptide comprising the amino acid sequence of SEQ ID NO:109.